What describes the procedures for tracking the investigational products, including placebos and comparators?

• A. Accountability procedures for the investigational products
• B. The labeling scheme only
• C. The distribution plan only
• D. Insurance coverage for trial products

Answer: (A)

Tracking investigational products hinges on accountability procedures that document every step of handling the IP from receipt to final disposition. These procedures create a complete trail: when an IP (including placebos and comparators) arrives at the site, how many units are received, batch or lot numbers, expiration dates, and where each unit is stored. As IPs are dispensed to trial subjects, the records must show exactly how many units were given, to whom, and under what conditions. When IPs are returned, used, or destroyed, the disposition must be recorded and reconciled against the amount that was dispensed. This ongoing reconciliation helps catch discrepancies, losses, or potential misuses, and supports patient safety and data integrity.

This framework goes beyond labeling or a distribution plan alone. Labeling ensures correct identification of products, but it does not by itself track quantities, locations, or final disposition. The distribution plan explains how IPs are sent to sites and subjects, but it does not establish the ongoing inventory control and reconciliation that accountability procedures require. Insurance coverage is not about tracking IPs and does not address how products are managed throughout the study.

In short, accountability procedures provide the comprehensive system for tracing every IP unit through the study, ensuring proper storage, dispensing, return, destruction, and reconciliation in line with regulatory requirements.